健康与遗传心理学研究室知识库

近年来, 内源性大麻素系统已被视为创伤后应激障碍(PTSD)未来药物治疗的新靶标。实证研究提示, 源性大麻素系统可能通过影响个体的恐惧记忆加工、焦虑与抑郁表型以及奖励与动机调控而参与了 PTSD的发生发展。应用适量的大麻素类物质可缓解 PTSD 症状, 尤其可以改善患者的睡眠问题。未来的研究应进一步明确内源性大麻素系统在 PTSD 病因学中的作用机制, 提高现有药用大麻素类物质的临床安全性, 并发展新型大麻素受体调节剂。另外, 探讨遗传因素和反应异质性在内源性大麻素治疗 PTSD 中的作用, 也将促进治疗人群的早期识别和精准医疗的发展。

Recently, endocannabinoid system has been proposed as a new pharmacological target of post-traumatic stress disorder (PTSD). Empirical studies indicated that endocannabinoid system is closely linked to the occurrence and development of PTSD due to its important roles in regulating the fear memory, anxiety, depression, reward as well as motivation. Several clinical studies also found that appropriate dose of cannabinoids can relieve PTSD symptoms, especially the sleep problems. Future studies should further explore the pathological mechanism of endocannabinoid system in PTSD, increase the clinical security of medicinal cannabinoids,and develop the new kinds of cannabinoid receptor modulators. In addition, investigating of the influence of genetic factors and heterogeneity of responses in the effect of endocannabinoid on treatment of PTSD will also promote the early identification of the patients and the development of precision medicine.